All News
Sjögren's disease RCTs: Has the Long Drought Ended?
Sjögren's disease has been a difficult space for new FDA approvals. At ACR 2025, two late breaking abstracts have triggered hope for patients suffering from Sjögren's disease.
Read Article
Tacrolimus in Lupus Nephritis Management
Prof. Sandra Navarra and colleagues compared the efficacy and safety of tacrolimus and glucocorticoids vs. mycophenolate mofetil (MMF) as a continuous induction-maintenance treatment for class III/IV+V lupus nephritis.
Read Article
ACR 2025 Rheumatology Round Up
Drs. Jack Cush & Arthur Kavanaugh, two of rheumatology’s most trusted voices, provide a breakdown of the latest breakthroughs and hottest topics in rheumatology from the 2025 ACR Convergence meeting in Chicago.
Read Article
If you missed this pattern, you missed an autoimmune classic
What’s it? https://t.co/zO48zPCkqP
DocXus docxusofficial ( View Tweet)
#ACR25 Abstract 1526
“Guidance for #Steroid Tapering in Systemic Lupus Erythematosus”
101 international experts reached Delphi consensus on CS tapering strategies in #SLE.
🔹 Practical guidance for real-world tapering across disease activity levels and organ involvement. https://t.co/GRlUz3Y3EP
Links:
Romatolog Nurullah_Akkoc ( View Tweet)
🍼 “Stop breastfeeding if on methotrexate” — that’s what we’ve always heard.
But here’s the news 👇
📊 Latest EULAR lactation: Methotrexate = LoE 4 / C
➡️ May be considered in breastfeeding if no safer alternative exists.
💡Not first-line, not forbidden — just evidence-limited. https://t.co/IJEpZYMaFV
Dr Abhilasha Manwatkar (AIIMS Nagpur) Abhilasha21822 ( View Tweet)
@Janetbirdope’s #ACR25 pearls remind us:
Order ANA only when clinical suspicion exists
Never repeat a positive ANA
ENA only if ANA+
❌ Ignore dsDNA if ANA– (except anti-Ro52)
Stop serial dsDNA/C3/C4 if stable
Smart lab use saves patients anxiety and systems money.
#SLE https://t.co/Mu3EefcIx0
Romatolog Nurullah_Akkoc ( View Tweet)
Really great visual summaries by Athena Chin, Sam Whittle and colleagues: Recs for the Use DMARDs in Pregnancy and Reproductive Health for Pts w Rheumatic Disease: A Scoping Review - Oct 2025 - Arthritis Care & Research #Rheumatology #MedEdu https://t.co/zRJcTESJWN 🇦🇺 https://t.co/OYZVtLEYr7
Links:
Suleman Bhana, MD DrBhana ( View Tweet)
Now published: The 2025 ACR Guideline for the Treatment of Systemic Lupus Erythematosus
📄 Read the paper: https://t.co/56eOK86lmn
ℹ️ See additional content and resources on this guideline at https://t.co/PVEyOkY14w https://t.co/cR4RVfWPlI
Links:
ACR_Journals ACR_Journals ( View Tweet)
Early Peripheral SpA: Is it okay to stop treatment sometimes?
Dr. Richard Conway reports on abstract 0568 "Drug-Free Remission in Early Peripheral Spondyloarthritis: 10-year follow-up from the CRESPA-trial," presented at #ACR25
https://t.co/FtI2o90v9O https://t.co/jUAEDZhDW5
Dr. John Cush RheumNow ( View Tweet)
Is Low Disease Activity Low Enough?
Drs. Jonathan Kay and Joel Kremer discuss abstract 0449, "Consistency of CDAI Low-Disease Activity (LDA) Outcomes with Time in a Large US Registry: Association With Patient-Reported Clinical Outcomes and Measures of Quality of Life". #ACR25 https://t.co/kI8qOYjVL4
Dr. John Cush RheumNow ( View Tweet)
GLP-1 Receptor Agonists: Impacts Beyond Metabolism?
Across multiple abstracts, investigators have used a large real-world dataset, the TriNetX network, to explore how GLP-1 receptor agonists (GLP-1RAs) might influence cardiovascular, renal and immune-mediated outcomes in our https://t.co/Xl6M3xSvlq
Dr. John Cush RheumNow ( View Tweet)
The Rapidly Evolving Landscape of Cellular and Immune-based Therapies
When Henry Ford unveiled the Model T in 1908, the automobile industry was forever changed. A similar transformation is now underway in rheumatology, where cellular and immune therapies are redefining how we https://t.co/RQuVETSTG4
Dr. John Cush RheumNow ( View Tweet)
💬 #ACR25 Topic Panels — LIVE!
Nov. 3 join RheumNow at 7 PM ET for a deep dives into the hottest topics in rheumatology:
👉 RA
Join Us Live on:
X • Facebook • YouTube • LinkedIn • https://t.co/V10S4oVFsv
Top experts. Real clinical insight. Don't miss these discussions https://t.co/i5UM0OBu86
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR25 - Day 1 Report
https://t.co/JayJCP9Rue https://t.co/B62mKbW4B8
Dr. John Cush RheumNow ( View Tweet)
"Personally I'm always ready to learn, although I do not always like being taught."
– Winston Churchill
Dr. John Cush RheumNow ( View Tweet)
Catching AxSpA Early: Closing the Diagnostic Gap
Dr. Akhil Sood reports on abstract 2635 and abstract 2636 presented at #ACR25.
https://t.co/TmJQKQUu9E https://t.co/6dWf8DY2W3
Dr. John Cush RheumNow ( View Tweet)
RA: Inject the Steroids
Dr. Richard Conway reports on abstract 1355, "Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance of being off steroids and escalation of therapy at 1 year," presented at the #ACR25. https://t.co/xFQMIpi75S
Dr. John Cush RheumNow ( View Tweet)
#ACR25 Best Abstracts - Day 1
The RheumNow Faculty have run through day one at ACR25 and come with a few of their favorites - some what you expect, but some of these are gems.
https://t.co/tYY5xGOEGU https://t.co/wpQbvEcH1f
Dr. John Cush RheumNow ( View Tweet)
New Gout Therapies Show Promise in Phase III Trials
At #ACR25, the American College of Rheumatology’s annual meeting, researchers presented pivotal Phase III studies highlighting novel therapeutic options for patients with gout, particularly those with limited treatment choices https://t.co/Ff16L2CHc0
Dr. John Cush RheumNow ( View Tweet)
